- Previous Close
0.0582 - Open
0.0587 - Bid 0.0751 x --
- Ask 0.1182 x --
- Day's Range
0.0587 - 0.0587 - 52 Week Range
0.0521 - 0.2565 - Volume
7,000 - Avg. Volume
366 - Market Cap (intraday)
8.653M - Beta (5Y Monthly) 1.58
- PE Ratio (TTM)
-- - EPS (TTM)
-0.1100 - Earnings Date Jun 18, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Biovica International AB (publ), a biotech company, develops and commercializes novel blood-based biomarker assays that enhance the monitoring and predicting of cancer therapies in the United States of America. It primarily focuses on breast cancer. The company develops DiviTum TKa, a blood-based biomarker assay that measures thymidine kinase activity, which is correlated with cell proliferation. It serves cancer institutes, pharmaceutical companies, and collaborative groups. Biovica International AB (publ) was incorporated in 2008 and is headquartered in Uppsala, Sweden.
www.biovica.comRecent News: 9II.F
View More
Performance Overview: 9II.F
Trailing total returns as of 3/26/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: 9II.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: 9II.F
View MoreValuation Measures
Market Cap
8.58M
Enterprise Value
5.17M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.87
Price/Book (mrq)
1.11
Enterprise Value/Revenue
6.92
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-55.31%
Return on Equity (ttm)
-106.13%
Revenue (ttm)
8.19M
Net Income Avi to Common (ttm)
-106.39M
Diluted EPS (ttm)
-0.1100
Balance Sheet and Cash Flow
Total Cash (mrq)
43.51M
Total Debt/Equity (mrq)
9.49%
Levered Free Cash Flow (ttm)
-56.02M
Research Analysis: 9II.F
View MoreCompany Insights: 9II.F
9II.F does not have Company Insights